Omnicell (NASDAQ:OMCL) Given New $65.00 Price Target at KeyCorp

Omnicell (NASDAQ:OMCL) had its price objective lowered by KeyCorp from $70.00 to $65.00 in a research note released on Friday morning, MarketBeat Ratings reports. KeyCorp currently has an overweight rating on the stock.

OMCL has been the topic of several other research reports. Zacks Research downgraded Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Wells Fargo & Company increased their target price on shares of Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Thursday, April 23rd. Craig Hallum restated a “buy” rating and set a $55.00 target price on shares of Omnicell in a research note on Wednesday, April 29th. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Finally, Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $58.43.

Omnicell Trading Down 4.7%

NASDAQ:OMCL opened at $35.37 on Friday. Omnicell has a one year low of $28.90 and a one year high of $55.00. The business has a fifty day moving average price of $41.97 and a 200-day moving average price of $41.09. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 42.11, a price-to-earnings-growth ratio of 0.96 and a beta of 0.96. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.29.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The company had revenue of $312.21 million for the quarter, compared to the consensus estimate of $310.21 million. During the same period in the previous year, the business earned $0.45 earnings per share. Omnicell’s quarterly revenue was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Sell-side analysts forecast that Omnicell will post 1.31 EPS for the current year.

Insider Buying and Selling at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 5,025 shares of Omnicell stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $217,180.50. Following the sale, the executive vice president directly owned 112,783 shares in the company, valued at approximately $4,874,481.26. The trade was a 4.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the sale, the executive vice president owned 154,785 shares in the company, valued at approximately $6,689,807.70. The trade was a 1.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.92% of the company’s stock.

Institutional Investors Weigh In On Omnicell

Several large investors have recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in shares of Omnicell in the second quarter worth about $26,000. Versant Capital Management Inc boosted its stake in Omnicell by 38.7% during the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after buying an additional 294 shares during the last quarter. Clearstead Advisors LLC grew its holdings in Omnicell by 12,180.0% during the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after buying an additional 1,218 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in Omnicell during the 4th quarter valued at approximately $58,000. Finally, Parkside Financial Bank & Trust grew its holdings in Omnicell by 1,708.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after buying an additional 1,264 shares in the last quarter. 97.70% of the stock is owned by institutional investors.

More Omnicell News

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Omnicell reported second-quarter adjusted EPS of $0.94, well above the $0.47–$0.48 consensus, while revenue rose 7.4% year over year to $312.2 million and also exceeded estimates. GAAP net income increased to $24 million from $6 million a year earlier. Omnicell Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised its full-year 2026 non-GAAP EPS outlook to $2.15–$2.30, above the roughly $1.81 analyst consensus, and lifted its full-year revenue outlook to $1.225–$1.245 billion. Demand for connected devices, technical services and SaaS offerings, along with cost controls and tariff refunds, supported results. Omnicell Q2 Non-GAAP Net Income, Revenue Increase; 2026 Non-GAAP EPS Outlook Lifted
• Positive Sentiment: Omnicell highlighted momentum in its Titan XT and OmniSphere platforms, pointing to pipeline growth and longer-term opportunities in medication-management automation. KeyCorp maintained an “overweight” rating, although it reduced its price target from $70 to $65. OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.